Association between Attention Deficit Hyperactivity Disorder Medication and Depression: A 10-year Follow-up Self-controlled Case Study
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Objective: There is clinical concern that the stimulant methylphenidate (MPH) might increase the risk of depression, particularly in children. This study aimed to investigate the association between MPH use and the risk of depression. Methods: A population-based electronic medical records database was used. We obtained claims data for prescription of ADHD medication, diagnosis of depression, and prescription of antidepressant medication between January 2007 and December 2016 for 43,259 individuals aged 6 to 19 who were diagnosed with ADHD between July 1, 2007 and December 31, 2007. The final analysis was based on 2,330 eligible participants. A self-controlled case series design was used to identify risk factors for major depressive disorder (MDD). Results: An elevated MDD risk was found during the 90 days before MPH exposure, with an incidence rate ratio (IRR) of 12.12 (95% confidence interval [95% CI]: 10.06−14.61, p ＜ 0.0001). During methylphenidate treatment, the IRR was 18.06 with a 95% CI of 16.67 to 19.56 (p ＜ 0.0001), but it returned to baseline levels after day 31 of MPH treatment discontinuation. The IRR for patients aged 6 to 9 years was 13.11 (95% CI: 9.58−17.95) during the 90 days before MPH exposure, and 17.7 (95% CI: 15.6−20.08) during MPH treatment, but returned to baseline levels after discontinuation of MPH treatment. Conclusion: We confirmed the temporal relationship between depression and methylphenidate use in young people with ADHD. Though the absolute risk is low, the risk of depression should be carefully considered, particularly in the period directly following the start of methylphenidate treatment.
Abstract
Objective: There is clinical concern that the stimulant methylphenidate (MPH) might increase the risk of depression, particularly in children. This study aimed to investigate the association between MPH use and the risk of depression. Methods: A population-based electronic medical records database was used. We obtained claims data for prescription of ADHD medication, diagnosis of depression, and prescription of antidepressant medication between January 2007 and December 2016 for 43,259 individuals aged 6 to 19 who were diagnosed with ADHD between July 1, 2007 and December 31, 2007. The final analysis was based on 2,330 eligible participants. A self-controlled case series design was used to identify risk factors for major depressive disorder (MDD). Results: An elevated MDD risk was found during the 90 days before MPH exposure, with an incidence rate ratio (IRR) of 12.12 (95% confidence interval [95% CI]: 10.06−14.61, p ＜ 0.0001). During methylphenidate treatment, the IRR was 18.06 with a 95% CI of 16.67 to 19.56 (p ＜ 0.0001), but it returned to baseline levels after day 31 of MPH treatment discontinuation. The IRR for patients aged 6 to 9 years was 13.11 (95% CI: 9.58−17.95) during the 90 days before MPH exposure, and 17.7 (95% CI: 15.6−20.08) during MPH treatment, but returned to baseline levels after discontinuation of MPH treatment. Conclusion: We confirmed the temporal relationship between depression and methylphenidate use in young people with ADHD. Though the absolute risk is low, the risk of depression should be carefully considered, particularly in the period directly following the start of methylphenidate treatment.
참고문헌 (40)
- Cho SC, "Full syndrome and subthreshold attention-deficit", hyperactivity disorder in a Korean community sample : comorbidity and temperament findings, 2009, pp.18, 447~457
- Park S, "Prevalence, correlates, and comorbidities of DSM-IV psychiatric disorders in children in Seoul, Korea", Asia Pac J Public Health, 27, pp.NP1942~NP1951 (2015)
- Polanczyk G, "The worldwide prevalence of ADHD : a systematic review and metaregression analysis", Am J Psychiatry, 164, pp.942~948 (2007)
- Barbaresi WJ, "Mortality, ADHD, and psychosocial adversity in adults with childhood ADHD : a prospective study", Pediatrics, 131, pp.637~644 (2013)
- Loe IM, "Academic and educational outcomes of children with ADHD", J Pediatr Psychol, 32, pp.643~654 (2007)
- Daviss WB, "A review of co-morbid depression in pediatric ADHD : etiology, phenomenology, and treatment", J Child Adolesc Psychopharmacol, 18, pp.565~571 (2008)
- Mitchison GM, "Prevalence and gender differences of ODD, anxiety, and depression in a sample of children with ADHD", J Atten Disord, 23, pp.1339~1345 (2019)
- Pliszka S, "Practice parameter for the assessment and treatment of children and adolescents with attention-deficit", hyperactivity disorder, 2007, pp.46, 894~921
- Beau-Lejdstrom R, "Latest trends in ADHD drug prescribing patterns in children in the UK : prevalence, incidence and persistence", BMJ Open, 6, pp.e010508~ (2016)
- Chai G, "Trends of outpatient prescription drug utilization in US children, 2002-2010", Pediatrics, 130, pp.23~31 (2012)
- Renoux C, "Prescribing trends of attention-deficit hyperactivity disorder(ADHD)medications in UK primary care, 1995-2015", Br J Clin Pharmacol, 82, pp.858~868 (2016)
- Song I, "Patient and provider characteristics related with prescribing of ADHD medication : nationwide health insurance claims database study in Korea", Asia Pac Psychiatry, 10, pp.e12289~ (2018)
- Greenhill L, "Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD", J Am Acad Child Adolesc Psychiatry, 45, pp.1284~1293 (2006)
- European Medicines Agency, "European Medicines Agency makes recommendations for safer use of Ritalin and other methylphenidate-containing medicines in the EU", European Medicines Agency, ~ (2009)
- Lavretsky H, "Methylphenidate augmentation of citalopram in elderly depressed patients", Am J Geriatr Psychiatry, 9, pp.298~303 (2001)
- Satel SL, "Stimulants in the treatment of depression : a critical overview", J Clin Psychiatry, 50, pp.241~249 (1989)
- Barr AM, "Psychostimulant withdrawal as an inducing condition in animal models of depression", Neurosci Biobehav Rev, 29, pp.675~706 (2005)
- Bolaños CA, "Methylphenidate treatment during pre-and periadolescence alters behavioral responses to emotional stimuli at adulthood", Biol Psychiatry, 54, pp.1317~1329 (2003)
- Chang Z, "Medication for attention-deficit", hyperactivity disorder and risk for depression : a nationwide longitudinal cohort study, 2016, pp.80, 916~922
- Chen Q, "Drug treatment for attention-deficit", hyperactivity disorder and suicidal behaviour : register based study, 2014, pp.348, g3769~
- Man KKC, "Association of risk of suicide attempts with methylphenidate treatment", JAMA Psychiatry, 74, pp.1048~1055 (2017)
- The operation of nationwide health insurance and its implications, "Kim J", Korea Institute for Health and Social Affiars, ~ (2012)
- World Health Organization, "ICD-10. International statistical classification of diseases and related health problems. Tenth revision", World Health Organization, ~ (2004)
- Shin JY, "Risk of ischemic stroke with the use of risperidone, quetiapine and olanzapine in elderly patients : a population-based, case-crossover study", J Psychopharmacol, 27, pp.638~644 (2013)
- 송선옥, "Background and Data Configuration Process of a Nationwide Population-Based Study Using the Korean National Health Insurance System", Diabetes and Metabolism Journal, 38(5), pp.395~403 (2014), 대한당뇨병학회[DOI]
- Whitaker HJ, "Tutorial in biostatistics : the self-controlled case series method", Stat Med, 25, pp.1768~1797 (2006)
- Whitaker HJ, "The methodology of self-controlled case series studies", Stat Methods Med Res, 18, pp.7~26 (2009)
- Uddin MJ, "Methods to control for unmeasured confounding in pharmacoepidemiology : an overview", Int J Clin Pharm, 38, pp.714~723 (2016)
- Lee MJ, "Attention-deficit hyperactivity disorder, its treatment with medication and the probability of developing a depressive disorder : a nationwide population-based study in Taiwan", J Affect Disord, 189, pp.110~117 (2016)
- Staikova E, "Childhood stimulant treatment and teen depression : is there a relationship?", J Child Adolesc Psychopharmacol, 20, pp.387~393 (2010)
- Jensen PS, "3-year follow-up of the NIMH MTA study", J Am Acad Child Adolesc Psychiatry, 46, pp.989~1002 (2007)
- Jaffe SL, "Intranasal abuse of prescribed methylphenidate by an alcohol and drug abusing adolescent with ADHD", J Am Acad Child Adolesc Psychiatry, 30, pp.773~775 (1991)
- Lakić A, "Depressive symptoms as a side effect of the sustained release form of methylphenidate in a 7-year-old boy with attention-deficit hyperactivity disorder", Vojnosanit Pregl, 69, pp.201~204 (2012)
- Madjar N, "Childhood methylphenidate adherence as a predictor of antidepressants use during adolescence", Eur Child Adolesc Psychiatry, 28, pp.1365~1373 (2019)
- Coletti DJ, "Parent perspectives on the decision to initiate medication treatment of attention-deficit", hyperactivity disorder, 2012, pp.22, 226~237
- 변희정, "Psychiatric Comorbidity in Korean Children and Adolescents with Attention-Deficit Hyperactivity Disorder: Psychopathology According to Subtype", Yonsei Medical Journal, 47(1), pp.113~121 (2006), 연세대학교의과대학
- Larson K, "Patterns of comorbidity, functioning, and service use for US children with ADHD, 2007", Pediatrics, 127, pp.462~470 (2011)
- Ferrari AJ, "Global variation in the prevalence and incidence of major depressive disorder : a systematic review of the epidemiological literature", Psychol Med, 43, pp.471~481 (2013)
- Yen S, "A cross-cultural comparison of depressive symptom manifestation : China and the United States", J Consult Clin Psychol, 68, pp.993~999 (2000)
- Whitlock FA, "Drugs and depression", Drugs, 15, pp.53~71 (1978)